The Ministry of Food and Drug Safety has approved a new drug for the treatment of ulcerative colitis, 'Ombuzy 20mg/mL (Mirikizumab)'. Ulcerative colitis is a chronic relapsing disease characterized by inflammation or ulcers in the colon.
On the 7th, the Ministry announced that it had approved Ombuzy, an ulcerative colitis treatment imported by Korea Lilly.
This treatment is a monoclonal antibody drug that treats ulcerative colitis by inhibiting interleukin receptor downstream signaling, which causes inflammatory responses.
The Ministry explained the efficacy and effects of Ombuzy as "treating moderate to severe active ulcerative colitis in adults aged 18 and over who do not adequately respond to conventional treatments or biological agents, or who are intolerant to them."
The Ministry stated, "We will continue to do our best to ensure that treatments with confirmed safety and efficacy are supplied promptly based on regulatory science."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
